Fumagalli, Valeria http://orcid.org/0000-0003-2583-2498
Ravà, Micol http://orcid.org/0000-0001-7606-8368
Marotta, Davide http://orcid.org/0000-0003-1918-050X
Di Lucia, Pietro
Bono, Elisa B.
Giustini, Leonardo
De Leo, Federica
Casalgrandi, Maura
Monteleone, Emanuele http://orcid.org/0000-0001-7440-900X
Mouro, Violette
Malpighi, Chiara
Perucchini, Chiara
Grillo, Marta
De Palma, Sara
Donnici, Lorena http://orcid.org/0000-0002-9153-9102
Marchese, Silvia http://orcid.org/0000-0003-3822-7174
Conti, Matteo
Muramatsu, Hiromi
Perlman, Stanley http://orcid.org/0000-0003-4213-2354
Pardi, Norbert http://orcid.org/0000-0003-1008-6242
Kuka, Mirela http://orcid.org/0000-0001-9418-1559
De Francesco, Raffaele http://orcid.org/0000-0001-8754-5123
Bianchi, Marco E. http://orcid.org/0000-0002-5329-6445
Guidotti, Luca G. http://orcid.org/0000-0002-0205-2678
Iannacone, Matteo http://orcid.org/0000-0002-9370-2671
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (19891, 22737)
Ministero dell'Istruzione, dell'Università e della Ricerca (PE00000007 (INF-ACT), PRIN 2022FMESXL, PE00000007 (INF-ACT))
Ministero dell'Istruzione, dell'Università e della Ricerca
Article History
Received: 27 September 2023
Accepted: 13 February 2024
First Online: 14 March 2024
Competing interests
: M.I. participated in advisory boards/consultantship for Asher Biotherapeutics, GentiBio, Clexio Biosciences, Sybilla Biotech, BlueJay Therapeutics, Bristol Myers Squibb, Aligos Therapeutics and receives funding from Asher Biotherapeutics and VIR Biotechnology. N.P. is named on patents describing the use of nucleoside-modified mRNA in LNPs as a vaccine platform. He has disclosed those interests fully to the University of Pennsylvania and has in place an approved plan for managing any potential conflicts arising from the licensing of those patents. He served on the mRNA strategic advisory board of Sanofi Pasteur in 2022 and is a member of the Scientific Advisory Board of AldexChem. The other authors declare no competing interests.